|Entry demography of the 41 patients of this study|
|Mean age (range)||33.6(15–78)||35.4(13–65)|
|Extent of UC||Total||17||10|
|Clinical course||Chronic continuous type||0||1|
|Relapsing remitting type||28||14|
|First UC episode||0||2|
|Patients with a history of exposure to PSL||17||13|
|Patients on AZA (50mg/day)||8||8|
GMA, adsorptive granulocyte and monocyte apheresis; PSL, predonisolone; AZA, azathioprine (started ≥8 weeks ahead of entry).
All patients were included following a relapse of ulcerative colitis (UC)
Tominaga et al.
Tominaga et al. BMC Gastroenterology 2013 13:41 doi:10.1186/1471-230X-13-41